Ullernchausséen 64
Oslo 0379
Norway
47 41 38 00 80
https://www.ultimovacs.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 24
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Carlos de Sousa | Chief Executive Officer | 5,51M | N/A | 1958 |
Mr. Hans Vassgard Eid | Chief Financial Officer | 3,15M | N/A | N/A |
Ms. Ingunn Hagen Westgaard Ph.D. | Head of Research | 1,78M | N/A | N/A |
Mr. Audun Tornes | Chief Technology Officer | 2,07M | N/A | N/A |
Ms. Anne H. Worsoe | Head of Investor Relations & ESG | 1,83M | N/A | N/A |
Mr. Jens Egil Torbjorn Bjorheim M.D., Ph.D. | Chief Medical Officer | 3,04M | N/A | N/A |
Mr. Oivind Foss Ph.D. | Head of Clinical Operations | 1,8M | N/A | N/A |
Ms. Gudrun Troite Ph.D. | Head of Project Coordination | 1,78M | N/A | N/A |
Mr. Antonius Berkien | Chief Business Officer | 3,29M | N/A | 1968 |
Orla Mc Callion | Head of Regulatory Affairs & QA | 1,7M | N/A | N/A |
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
El ISS Governance QualityScore de Ultimovacs ASA, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.